Benefit and risk of prolonged dual antiplatelet therapy after drug-eluting stent implantation in patients with chronic kidney disease: a nationwide cohort study
| Autor: | Choongki Kim, Dong-Woo Choi, Seung-Jun Lee, Yongsung Suh, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Eun-Cheol Park, Yangsoo Jang, Chung-Mo Nam, Myeong-Ki Hong |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Time Factors
Myocardial Infarction Drug-Eluting Stents Hemorrhage Coronary Artery Disease Cohort Studies Percutaneous Coronary Intervention Treatment Outcome Humans Drug Therapy Combination Renal Insufficiency Chronic Cardiology and Cardiovascular Medicine Platelet Aggregation Inhibitors Retrospective Studies |
| ISSN: | 0471-5594 |
| DOI: | 10.21203/rs.3.rs-1349452/v1 |
| Popis: | Purpose: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with drug-eluting stent in patients with chronic kidney disease (CKD) is not clearly established. This study purposed to compare clinical outcomes of patients with 6-12 (standard) versus 12-24 months (prolonged) DAPT according to CKD.Methods: Using a nationwide, claim-based database, we retrospectively evaluated association between DAPT duration and clinical outcomes including death, composite ischemic event, and composite bleeding event between 1 and 3 years after PCI. CKD was defined as estimated glomerular filtration rate 2. Of 73,941 eligible patients, 13,425 (18.2%) had CKD and 49,019 (66%) were prescribed prolonged DAPT. Prolonged DAPT had no significant impact on the risk of clinical outcomes in patients with normal renal function.Results: In patients with CKD, prolonged DAPT was associated with a lower risk of all-cause death (HR 0.85, 95% CI 0.76–0.95) and composite ischemic events (HR 0.87, 95% CI 0.78–0.96) and a higher risk of composite bleeding events (HR 1.18, 95% CI 1.02–1.37). Benefit of prolonged DAPT on reducing composite ischemic event increased significantly in patients with worsened renal dysfunction (Pinteraction=0.02) while there was no significant interaction between its bleeding risk and renal dysfunction (Pinteraction=0.22).Conclusion: While standard DAPT would be recommended in patients with normal renal function, tailored decision for DAPT duration would be considered in those with CKD to balance between ischemic and bleeding risks. Trial registration: ClinicalTrial.gov (NCT04715594). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|